CClinicalTrials.gg
RecruitingNCT03059043Updated Aug 18, 2026

Safety and Efficacy Study of A Viscoelastic-free Method for Implantable Collamer Lens (ICL) Implantation

An interventional study of viscoelastic-free implantation system and standard viscoelastic-assisted Implantation system in Myopia, sponsored by Wenzhou Medical University. Recruiting at 5 sites in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Wenzhou Medical University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study evaluates the safety and efficacy of a viscoelastic-free method for Implantable Collamer Lens(ICL) implantation to treat high myopia. The subjects undergo randomization of ICL implantation using the viscoelastic-free method on one eye and undergoing standard method on the other one. The post-operative data are collected for analysis.

Read the detailed description

Implantable Collamer Lens(ICL) implantation has been proved to be an effective refractive option for surgical correction of high myopia. Currently, standard method utilizing the viscoelastic agent to fill and maintain the anterior chamber during the implantation, this requires an additional step to remove the viscoelastic agent at the end of the surgery and may cause the intraocular pressure spike in the early post-operative phase due to the incomplete removal of the viscoelastics. The new method is viscoelastic-free, which can be achieved by using balanced salt solution irrigation during the implantation.

This study is a prospective, randomized, paired-eye study to compare the safety and efficacy of the viscoelastic-free method with the standard method. Subjects enrolled in the study will be randomized to receive viscoelastic-free method on one eye and undergo standard method on the other one.The clinical outcomes of two groups will be assessed at several follow-ups: 2 hours, 1 day, 1 week, 1 month, 3 months and 6 months post-operatively.

02

Conditions studied

  • Myopia

Browse trials for

Keywords

  • Phakic Intraocular Lenses
  • viscoelastic
03

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Documented stable refraction for at least 1 year(within 0.5D)
  • Best spectacle-corrected visual acuity (BCVA) of 20/40 or better
  • Clear central cornea
  • -0.5D to -18.0D of myopic refractive error
  • Normal anterior chamber depth at least 2.8 mm to endothelium
  • Endothelial cell density (ECD) more than 2000 cell/mm2
  • Pupil diameter smaller than 7.0 mm under mesopic condition
  • Discontinued 3 weeks for hard contact lens and 1 week for soft contact lens wear

Exclusion criteria

Exclusion Criteria:

  • Preexisting ocular diseases or conditions other than myopia, evidence of progressive or acute ocular disease
  • Evidence of connective tissue disease or other systemic diseases that may confound the results of the study;
  • Narrow angle of anterior chamber
  • Pregnant, lactating, or planning to become pregnant during the course of the trial
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    viscoelastic-free system

    Eyes in this group will use viscoelastic-free implantation system during the surgery

    Device: viscoelastic-free implantation system

  • Active comparator
    viscoelastic-assisted system

    Eyes in this group will utilize the standard viscoelastic-assisted Implantation system during the surgery

    Device: standard viscoelastic-assisted Implantation system

Interventions

  • Deviceviscoelastic-free implantation system

    Viscoelastic-free implantation system use balanced salt solution irrigation during the implantation

  • Devicestandard viscoelastic-assisted Implantation system

    This method utilize the viscoelastic agent to fill and maintain the anterior chamber during the implantation

05

What researchers measure

Primary outcomes

  1. Early Post-operative Intraocular Pressure

    Intraocular Pressure measured by non-contact tonometers

    Time frame: 2 hours after surgery

Secondary outcomes

  1. Corrected Visual Acuity (UCVA) at Distance

    Subjective refraction

    Time frame: baseline, 1 day, 1 week, 1 month, 3 months and 6 months after surgery

  2. Uncorrected Visual Acuity (UCVA) at Distance

    Measure by visual acuity chart

    Time frame: baseline, 1 day, 1 week, 1 month, 3 months and 6 months after surgery

  3. Endothelial Cell Density

    Measure by Specular Microscope

    Time frame: baseline, 1 month, 3 months and 6 months after surgery

  4. Vault measured by anterior segment OCT

    Vault measured by anterior segment OCT

    Time frame: 2 hours, 1 day, 1 week, 1 month, 3 months and 6 months after surgery

  5. Intraocular Pressure

    Intraocular Pressure measured by non-contact tonometers

    Time frame: baseline, 1 day, 1 week, 1 month, 3 months and 6 months after surgery

  6. Refractive error (by Phoropter)

    subjective refraction by Phoropter

    Time frame: baseline, 1 day, 1 week, 1 month, 3 months and 6 months after surgery

  7. Anterior chamber reaction (by a laser flare meter)

    anterior chamber flare value was examined by a laser flare meter

    Time frame: baseline, 2 hours, 1 day, 1 week after surgery

  8. Duration of operation

    Time from the first incision is made to the end of the surgery

    Time frame: at the time of the surgery

  9. Complications of ICL implantation

    Lens opacities, Cataract surgery, Pupillary block, Ocular hypertension or glaucoma

    Time frame: up to 6 months after surgery

06

Study locations

1 of 5 sites recruiting
  • Guangdong General Hospital
    Guangzhou, Guangdong 510000, China
    • Jin Zeng, MD. · Contact
    Not yet recruiting
  • Hunan Provincial People's Hospital
    Changsha, Hunan 410000, China
    • Hua Wang, MD. · Contact
    Not yet recruiting
  • The Eye Hispital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
    • Anpeng Pan, MD.OD. · Contact · pananpeng@126.com · +86-577-88068809
    • Shuangqian Zhu, MD. · Sub investigator
    • Kaijing Zhou, MD.PhD. · Sub investigator
    Recruiting
  • Peking Union Medical College Hospital
    Beijing, 100000, China
    • Yan Luo, MD. · Contact
    Not yet recruiting
  • Shanghai Ninth People's Hospital
    Shanghai, 200000, China
    • Jibo Zhou, MD. · Contact
    Not yet recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03059043
Lead sponsor
Wenzhou Medical University
Responsible party
A-Yong Yu (Director of the Cataract Clinical Center, Wenzhou Medical University) — Principal investigator
First posted
Feb 23, 2017
Start date
Nov 16, 2018
Primary completion
Jun 22, 2028 (estimated)
Completion
Jun 22, 2028 (estimated)
Last update
Aug 18, 2026

Study contacts

AYong Yu, MD. PhD.
Contact
yaybetter@hotmail.com
+86-0577-88068880
Anpeng Pan, MD.OD.
Contact
pananpeng@126.com
AYong Yu, MD. PhD.
principal investigator · Wenzhou Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion